Gain Therapeutics Inc. Common Stock (GANX)
Stock · NASDAQ · Health Care
$1.26as of 10/16/2026
Price chart
Active signals
GANX Signal Track Record
How signals performed across all stocks →What GANX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -4.1% | 37% | September 29, 2026 |
| Bollinger Band Breakout | 23 | 0.0% | 48% | September 22, 2026 |
| Bollinger Band BreakdownActive now | 19 | -4.5% | 42% | May 18, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -6.3% | 40% | April 15, 2026 |
| Any 20-session window (baseline) | -2.6% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 20
- Website
- www.gaintherapeutics.com/
Fundamentals
- 1-day range
- $1.31$1.41
- Market cap
- $75.92M
- P/E (trailing)
- —
- P/E (forward)
- -1.93
- EPS (trailing)
- $-0.51
- Dividend yield
- —
- Beta
- 0.21
- Avg. volume
- 466.1K
How Gain Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2023 annual results
Source: 10-K filed Mar 26, 2024 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Gain Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- NMADNomad Power Solutions Inc. Common Stock$3.88▼ 5.13%Market cap $75.50MP/E —$3.12$7.7
- OSTXOS Therapies Incorporated Common Stock$1.32▼ 6.38%Market cap $74.23MP/E —$1.15$2.25
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $3.88 | ▼ 5.13% | $3.12$7.7 |
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.32 | ▼ 6.38% | $1.15$2.25 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Gain Therapeutics to Attend the 2026 Maxim Growth SummitYahoo · 10/8/2026
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Targetbenzinga · 10/5/2026
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price TargetBenzinga · 10/5/2026
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationYahoo · 10/1/2026
- Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of RexaceractBenzinga · 10/1/2026
- Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next YearBenzinga · 10/1/2026
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement DisordersYahoo · 9/29/2026
- Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement DisordersBenzinga · 9/29/2026
- Gain Therapeutics Appoints CEO Gene Mack As Interim CFO, Effective Oct. 1, Succeeding Principal Financial Officer Gianluca FuggettaBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Khalid Islam · July 15, 2026 · Grant25.0K
- Claude Nicaise · July 15, 2026 · Grant25.0K
- Gwen A. Melincoff · July 15, 2026 · Grant25.0K
- HASLER HANS PETER · July 15, 2026 · Grant25.0K
- Dov A. Goldstein, MD · July 15, 2026 · Grant25.0K
- Jeffrey Scott Riley · July 15, 2026 · Grant25.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 8.05M
- Total value held
- $13.81M
- Institutional holders
- 38
- Unknown1.77M
- Unknown1.01M
- Unknown631.6K
- Unknown568.6K
- Unknown566.1K
- Unknown469.6K
- Unknown447.3K
- Unknown399.9K
- Unknown312.5K
- Unknown255.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO
Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO. Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.